Log in
NASDAQ:GRAY

Graybug Vision Stock Forecast, Price & News

$13.16
-0.93 (-6.60 %)
(As of 10/30/2020 12:00 AM ET)
Add
Compare
Today's Range
$12.72
Now: $13.16
$14.24
50-Day Range N/A
52-Week Range
$12.50
Now: $13.16
$20.74
Volume120,927 shs
Average Volume131,013 shs
Market Capitalization$264.42 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Graybug Vision, Inc., a clinical stage biopharmaceutical company, develops medicines for the treatment of diseases of the retina and optic nerve. Its lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. The company is also developing GB-103, a once-a-year formulation of GB-102, for the treatment of diabetic retinopathy; and GB-401, a depot formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was founded in 2011 and is based in Redwood City, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 4.5Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.50 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GRAY
CUSIPN/A
CIKN/A
Phone650-487-2800
Employees24

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Market Cap$264.42 million
Next Earnings DateN/A
OptionableNot Optionable
$13.16
-0.93 (-6.60 %)
(As of 10/30/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GRAY News and Ratings via Email

Sign-up to receive the latest news and ratings for GRAY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Graybug Vision (NASDAQ:GRAY) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Graybug Vision?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Graybug Vision in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Graybug Vision
.

What price target have analysts set for GRAY?

6 analysts have issued twelve-month price targets for Graybug Vision's stock. Their forecasts range from $27.00 to $41.00. On average, they anticipate Graybug Vision's stock price to reach $33.50 in the next year. This suggests a possible upside of 154.6% from the stock's current price.
View analysts' price targets for Graybug Vision
.

Who are some of Graybug Vision's key competitors?

Who are Graybug Vision's key executives?

Graybug Vision's management team includes the following people:
  • Dr. Frederic Guerard Pharm.D., Pres, CEO & Director (Age 48)
  • Dr. Peter A. Campochiaro, Co-Founder and Member of Retina Clinical Advisory Board
  • Dr. Peter J. McDonnell, Co-Founder (Age 61)
  • Mr. Robert S. Breuil, Chief Financial Officer (Age 58)
  • Mr. Daniel Salain, Chief Technical Operations Officer (Age 53)

When did Graybug Vision IPO?

(GRAY) raised $75 million in an initial public offering (IPO) on Friday, September 25th 2020. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. SVB Leerink and Piper Sandler acted as the underwriters for the IPO and Needham & Co. and Wedbush PacGrow were co-managers.

What is Graybug Vision's stock symbol?

Graybug Vision trades on the NASDAQ under the ticker symbol "GRAY."

When does the company's quiet period expire?

Graybug Vision's quiet period expires on Wednesday, November 4th. Graybug Vision had issued 5,625,000 shares in its initial public offering on September 25th. The total size of the offering was $90,000,000 based on an initial share price of $16.00. During the company's quiet period, underwriters and any insiders involved in the IPO are restricted from issuing any research reports for the company because of SEC regulations. Following the expiration of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

How do I buy shares of Graybug Vision?

Shares of GRAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Graybug Vision's stock price today?

One share of GRAY stock can currently be purchased for approximately $13.16.

How big of a company is Graybug Vision?

Graybug Vision has a market capitalization of $264.42 million. Graybug Vision employs 24 workers across the globe.

What is Graybug Vision's official website?

The official website for Graybug Vision is www.graybug.com.

How can I contact Graybug Vision?

The company can be reached via phone at 650-487-2800 or via email at [email protected]

This page was last updated on 10/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.